Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21249927 | 0.85 | BRD4 (0.63) | BRD4HTTALDH1A1MAPTNPC1 | |
| SCHEMBL16723013 | 0.85 | BRD4 (0.63) | BRD4HTTMAPT | |
| SCHEMBL18067025 | 0.85 | BRD4 (0.59) | BRD4HTTALDH1A1MAPT | |
| SCHEMBL17021673 | 0.84 | BRD4 (0.62) | BRD4HTTMAPTNPC1RAB9A | |
| SCHEMBL16722565 | 0.84 | BRD4 (0.73) | BRD4HTTALDH1A1MAPTNPC1 | |
| SCHEMBL21674980 | 0.84 | BRD4 (0.73) | BRD4HTTALDH1A1MAPTNPC1 | |
| SCHEMBL16722998 | 0.83 | BRD4 (0.67) | BRD4HTTALDH1A1MAPTRAB9A | |
| SCHEMBL21531959 | 0.82 | BRD4 (0.59) | BRD4HTTALDH1A1MAPTNPC1 | |
| SCHEMBL17021684 | 0.82 | BRD4 (0.64) | BRD4HTTALDH1A1MAPTNPC1 | |
| SCHEMBL18067102 | 0.82 | BRD4 (0.64) | BRD4HTTMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160256458-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256458-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | BRD4 1/4885HTT 2378/4885ALDH1A1 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.